Published on February 9, 2013 at 4:43 AM
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has completed its acquisition of YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM).
On February 8, 2013, a subsidiary of Gilead acquired all of the outstanding common shares of YM pursuant to the terms of a plan of arrangement. As a result, YM has become a wholly-owned subsidiary of Gilead and it is anticipated that the common shares of YM will no longer be listed for trading on the NYSE MKT LLC or the Toronto Stock Exchange, on or about February 12, 2013. Shareholders of YM on this date will be entitled to receive U.S. $2.95 per common share in cash, and holders of warrants and stock options will be entitled to receive a cash payment equal to the difference between U.S. $2.95 and the exercise price of such warrant or stock option.
Source: Gilead Sciences